Compare TG Therapeutics Inc (TGTX) vs Western Digital Corp (WDC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Western Digital Corp — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while Western Digital Corp trades at $553.57 (market cap $168.00B). The key difference: Western Digital Corp is far larger — about 20.3× TG Therapeutics Inc's market cap, and Western Digital Corp pays a 0.12% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | WDC | |
|---|---|---|
Market Cap | $8.26B | $168.00B |
Sector | Health | Technology |
52-Week High | $59.06 | $746.23 |
52-Week Low | $26.39 | $67.06 |
Enterprise Value | $8.50B | $166.35B |
Dividend Yield | — | 0.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Western Digital (WDC) trades at $548.07, up 14.85% over 24 hours, reflecting strong momentum in memory stocks. The stock exhibits a bearish technical signal but has beaten earnings estimates for three consecutive quarters. Key financials show robust profitability with a net income margin of 55.07% and ROE of 37.73%. Recent news highlights WDC's position in the AI-driven memory and storage rebound, with institutional buying activity noted.
Outlook remains positive given analyst consensus and AI-driven demand, though valuation multiples are elevated. Risks include market volatility and competitive pressures. The consensus price target of $619.07 suggests potential upside, supported by strong institutional sentiment and fundamental improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Western Digital Corp
Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →
